Eisai Company, Limited

Kabushiki Kaisha Tokai Rika Denki Seisakusho

Yasuo Miyake

Sumio Watanabe

Takayuki Ohwaki

Masahiro Kawahara

Naoki Asakawa

Shigeru Sakashita

Hidenobu Andoh

Yasuo Ishibashi

Teiichi Hattori

Masaki Ichikawa

Takeshi Nakagawa

Fumio Kakimoto

Sadao Kokubu

Kazuhisa Kubota

Hisashi Hirose

Takao Sakakibara

Hidenobu Ando

Toshinobu Miwa

Mitsutoshi Higuchi

Kiyoshi Iwamoto

Toshikazu Mizutani

Yasuharu Saeki

Ichiro Yamakawa

Nobutaka Noda

Satoru Imaeda

Aishin Shinoda

Shinji Mizutani

Takeshi Watanabe

Sinzi Mizutani

Fumio Sagami

Yuichiro Hayashi

Takehiko Niwa

Haruo Shimura

Takeshi Miyakawa

Teruyoshi Nasu

Masanori Tsuno

Susumu Iwagiri

Female terminal

A sustained-release multi-granule tablet is obtained by compressing sustained-release granules, which contains a basis, and a formulation adjuvant. Each of the granules has been coated in advance with a layer of the formulation adjuvant and/or a layer of a mixture of the formulation adjuvant and the basis. The tablet releases an active substance at a suitable velocity into the digestion tract, resulting in that the inbalance in the absorption of the drug in each patient and among individual patients is minimized to achieve maximum bioavailability.

Sustained-release multi-granule tablet

A sustained-release multi-granule tablet is obtained by compressing sustained-release granules, which contains an active substance, and a formulation adjuvant. Each of the granules has been coated in advance with a layer of the formulation adjuvant and/or a layer of a mixture of the formulation adjuvant and the active substance. The tablet releases an active substance at a suitable velocity into the digestion tract, resulting in that the variability in the absorption of the drug in each patient and among individual patients is minimized to achieve maximum bioavailability.

An injection composition comprises a pharmacologically effective amount of a modified tPA, 47.5 mM or more of an amino acid or a salt thereof and is improved in view of stability and solubility.

Modified tPA-containing injection composition having increased solubility

A conjugate formed by the covalent bonding of a prostaglandin or a similar compound thereto and a polysaccharide. The prostaglandin is selected from prostaglandin E1, prostaglandin E2, prostaglandin F2.alpha., prostaglandin I2, carbacycline and iloprost and the polysaccharide is selected from pluran, amylose, amylopectin, cellulose, dextran and hydroxyethylated starch.

Conjugate of prostaglandin and polysaccharide

A multilayer granule of the invention comprises a core, a slow-release layer, a rapid-release layer to be provided outer of said slow-release layer and a film layer containing a metal stearate and being deposited between the slow-release layer and the rapid-release layer. A pharmacologically effective component is kept to discharge for long.

Multilayer sustained release granule

A separating agent comprising ovomucoid and a carrier is useful to separate an optical isomer from a racemoid by way of chromatography.

Separation agent for optical isomers

A sustained-release drug preparation comprises a water-soluble drug, a lipidic substance and an oil as its essential components. The drug level in the blood is sustained at a preferable concentation for a long period of time.

Sustained-release drug preparation

A medical composition which contains a tissue Plasminogen Activator (tPA) in combination with meglumine or a salt thereof.

tPA-containing medical composition

A granule of drug to remain in the stomach comprises a core comprising a pharmaceutically effective ingredient, a foaming layer coated on said core and an expansive film coated on said layer.

Granule remaining in stomach

A composition containing a tissue Plasminogen Activator (tPA) which comprises a partial hydrolyzate of gelatin cross-linked to a diisocyanate as an essential ingredient; or alternatively a partial hydrolyzate of gelatin cross-linked to a diisocyanate and one or more of a basic amino acid or salt thereof. The composition enhances the solubility of the tPA in water, thereby making the tPA further available in the treatment of circulatory diseases caused by thrombi.

Composition containing tissue plasminogen activator

A composition containing ubidecarenone, a glycerol mono-fatty acid ester and/or a propylene glycol mono-fatty acid ester, and a liquid oil. Oral administration of the composition provides a promoted absorption of ubidecarenone which is used for improving a coronary function.

Composition containing ubidecarenone with absorption promoted

A device for coupling two rotary shafts, wherein a guide member is used on the coupling end of a first shaft to guide a coupling protrusion on the coupling end of a second shaft into a V-shaped coupling recess on the first shaft. The guide member can be made of a resilient plastic, to provide a flexible and detachable coupling member and reduce abnormal wear of the rotary shaft.

Rotary shaft coupling device

An automotive steering assembly which has a steering pad maintained stationary independently of the steering wheel operation is disclosed. The assembly employs a sun and planetary gear system in transmission of rotary motion to the steering shaft. The steering wheel is rigidly attached to the steering shaft while the sun and planetary gear system contributes to maintenance of the orientation of the steering pad. In the sun and planetary gear system, the role of the sun portion is played by a timing belt whereas that of the planetary portion is played by a rotary gear wheel. The above timing belt and planetary gear wheel are adapted to be disengaged from each other upon entry of foreign matters including sand grains or the like.

Automotive steering assembly

An inclusion compound composed of tripamide and cyclodextrin markedly improves the solubility of tripamide which is effective for treatment of essential hypertension.

Growing community of inventors

Aichi, Japan

Yasuo Miyake